These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 32456488)

  • 21. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
    Falcon O; Auer M; Gerovassili A; Spencer K; Nicolaides KH
    Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Screening for aneuploidies by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-13+6 gestational weeks.
    Karadzov-Orlić N; Egić A; Filimonović D; Marinković M; Damnjanović-Pazin B; Milovanović Z; Joksić I; Branković S; Lukić R; Mandić V; Cerović N; Mojović D; Plamenac S; Stanković M; Maglić D; Mikovć Z
    Srp Arh Celok Lek; 2012; 140(9-10):606-11. PubMed ID: 23289277
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The predictive value of the first trimester combined test for gestational diabetes mellitus.
    Yildiz A; Yozgat ST; Cokmez H; Yildiz FŞ
    Ginekol Pol; 2023; 94(5):395-399. PubMed ID: 35894505
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of Rhesus status on first-trimester pregnancy screening markers free beta human chorionic gonadotropin, pregnancy-associated plasma protein-A and nuchal translucency.
    Cowans NJ; Stamatopoulou A; Spencer K
    Prenat Diagn; 2009 May; 29(5):505-7. PubMed ID: 19222026
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does progesterone therapy increase nuchal translucency in women with threatened miscarriage?
    Keçecioğlu M; Tokmak A; Keçecioğlu TS; Akselim B; Karakaya BK; Taşçı Y
    Ginekol Pol; 2016; 87(5):390-4. PubMed ID: 27304657
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does diurnal variation affect the first trimester fetal aneuploidy screening test biochemical parameters of fetuses with normal nuchal translucency?
    Karsli MF; Cakmak B; Seckin KD; Akkas Yilmaz E; Akgul G; Togrul C; Kucukozkan T
    J Matern Fetal Neonatal Med; 2016; 29(11):1808-11. PubMed ID: 26135776
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined measurement of fetal nuchal translucency, maternal serum free beta-hCG, and pregnancy-associated plasma protein A for first-trimester Down's syndrome screening.
    Tsai MS; Huang YY; Hwa KY; Cheng CC; Lee FK
    J Formos Med Assoc; 2001 May; 100(5):319-25. PubMed ID: 11432311
    [TBL] [Abstract][Full Text] [Related]  

  • 28. First trimester maternal serum free β-human chorionic gonadotropin and pregnancy-associated plasma protein A in pregnancies complicated by diabetes mellitus.
    Savvidou MD; Syngelaki A; Muhaisen M; Emelyanenko E; Nicolaides KH
    BJOG; 2012 Mar; 119(4):410-6. PubMed ID: 22324916
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First-trimester combined screening for trisomy 21 with different combinations of placental growth factor, free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Kagan KO; Hoopmann M; Abele H; Alkier R; Lüthgens K
    Ultrasound Obstet Gynecol; 2012 Nov; 40(5):530-5. PubMed ID: 22611005
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Do we need readjustment of the biochemical parameters in first trimester combined aneuploidy screening test in women with polycystic ovary syndrome?
    Karsli MF; Gultekin IB; Cakmak B; Yeral MI; Seckin KD; Alt Nboga O; Kucukozkan T
    Prenat Diagn; 2014 Nov; 34(11):1073-6. PubMed ID: 24916516
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ADAM 12 as a first-trimester maternal serum marker in screening for Down syndrome.
    Laigaard J; Spencer K; Christiansen M; Cowans NJ; Larsen SO; Pedersen BN; Wewer UM
    Prenat Diagn; 2006 Oct; 26(10):973-9. PubMed ID: 16892462
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Screening for trisomy at 11-13 weeks' gestation: use of pregnancy-associated plasma protein-A, placental growth factor or both.
    Mazer Zumaeta A; Wright A; Syngelaki A; Maritsa VA; Bardani E; Nicolaides KH
    Ultrasound Obstet Gynecol; 2020 Sep; 56(3):408-415. PubMed ID: 32621353
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of inherited thrombophilia on first trimester combined aneuploidy screening test parameters.
    Karsli MF; Baser E; Seckin KD; Yeral Mİ; Togrul C; Ugur M
    J Matern Fetal Neonatal Med; 2014 Mar; 27(4):346-9. PubMed ID: 23795618
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of correcting for smoking status when screening for chromosomal anomalies using maternal serum biochemistry and fetal nuchal translucency thickness in the first trimester of pregnancy.
    Spencer K; Bindra R; Cacho AM; Nicolaides KH
    Prenat Diagn; 2004 Mar; 24(3):169-73. PubMed ID: 15057947
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of a 'vanishing twin' on biochemical and ultrasound first trimester screening markers for Down's syndrome in pregnancies conceived by assisted reproductive technology.
    Gjerris AC; Loft A; Pinborg A; Christiansen M; Tabor A
    Hum Reprod; 2009 Jan; 24(1):55-62. PubMed ID: 18835870
    [TBL] [Abstract][Full Text] [Related]  

  • 36. First-trimester biochemical markers of aneuploidy and the prediction of small-for-gestational age fetuses.
    Spencer K; Cowans NJ; Avgidou K; Molina F; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Jan; 31(1):15-9. PubMed ID: 17999381
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of bias in serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A multiples of the median levels on first-trimester screening for trisomy 21.
    Wright D; Abele H; Baker A; Kagan KO
    Ultrasound Obstet Gynecol; 2011 Sep; 38(3):309-13. PubMed ID: 21400623
    [TBL] [Abstract][Full Text] [Related]  

  • 38. First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics.
    Kagan KO; Wright D; Spencer K; Molina FS; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 May; 31(5):493-502. PubMed ID: 18432600
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A prospective cohort study on association of first-trimester serum biomarkers and risk of isolated foetal congenital heart defects.
    Hematian MN; Hessami K; Torabi S; Saleh M; Nouri B; Saleh M
    Biomarkers; 2021 Dec; 26(8):747-751. PubMed ID: 34645361
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modeling Down syndrome screening performance using first-trimester serum markers.
    Koster MP; Wortelboer EJ; Stoutenbeek P; Visser GH; Schielen PC
    Ultrasound Obstet Gynecol; 2011 Aug; 38(2):134-9. PubMed ID: 21800388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.